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Increased sodium-lithium countertransport activity in red cells of IgA
nephropathy patients. The aim of this work was to analyze Na,Li
countertransport activity in the erythrocytes from patients with IgA
nephropathy, in relationship with their blood pressure status and lipid
profile. Forty-nine patients (32 males, 17 females) with biopsy-proven
IgA nephropathy and without significant impairment of renal function
(serum creatinine  1.4 mg/dl) and 36 normal subjects (21 males, 15
females) were evaluated. Twenty-nine patients with IgA nephropathy
were normotensive and 20 hypertensive (diastolic pressure > 95 mm Hg
or treated by antihypertensive drugs). Na,Li countertransport was
significantly higher in red cells from hypertensive than from normoten-
sive patients (P = 0.002) and normal subjects (P = 0.0001), (values
respectively 309 17; 241 12 and 211 11 smol/liter RBC/hr);
normotensive patients with IgA nephropathy did not differ from con-
trols regarding the Na,Li countertransport rate. A multiple stepwise
logistic regression analysis with blood pressure status as the dependent
variable and Na,Li countertransport activity, age, serum creatinine,
proteinuria, cholesterol, triglycerides, plasma potassium and time from
onset as independent variables, indicated an independent significant
association for Na,Li countertransport (P = 0.002) proteinuria (P
0.006), plasma potassium (P = 0.006) and age (P = 0.029). Other tested
variables were not independently related to blood pressure status.
Hyperlipidemic patients (plasma total cholesterol concentration >200
mg/dl and/or plasma triglycerides >172 mgldl) had an erythrocyte Na,Li
countertransport activity significantly higher than normolipidemic (P =
0.005) and controls (P = 0.001) (values respectively 295 14; 226 12
and 211 11 imol/liter RBCIhr). A high erythrocyte Na,Li counter-
transport rate may be a marker of an increased risk of developing
arterial hypertension, lipid abnormalities, and perhaps a more severe
renal disease in IgA nephropathy.
Since the first report from Canessa et al 11], several studies
[2—5] have suggested that in the general population a high
erythrocyte Na,Li countertransport rate may be considered a
genetic marker for a subgroup of essential hypertensives.
Moreover, an abnormal erythrocyte Na,Li countertransport
activity may be linked to the development of cardiovascular and
renal complications in essential hypertensive patients [6—8], and
has been found in type I diabetic patients with clinical evidence
of nephropathy and/or hypertension [9—13].
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IgA nephropathy is the most common type of primary gb-
merulonephritis in many countries [14]. The long-term progno-
sis of this disease is not uniform, and up to 30% of the patients
progress to end-stage renal failure. The immune system is
involved in the pathogenesis of the disease [15]. However,
non-immunologically-mediated mechanisms seem to play a role
in its progression: arterial hypertension is a marker of poor
prognosis [16, 17], and the development of renal vascular
lesions might play a major role in the development of chronic
renal failure [18].
Furthermore, it has been recently suggested that patients
with primary chronic glomerulonephritis, including IgA
nephropathy, have an increased genetic risk of hypertension
[19].
Hence, aim of this study was to evaluate Na,Li countertrans-
port activity in erythrocytes from patients with IgA nephrop-
athy, in relationship with their blood pressure status and
laboratory findings.
Methods
Subjects
Forty-nine patients (32 males, 17 females) with biopsy-
proven primary IgA nephropathy and without significant im-
pairment of renal function (serum creatinine s 1.4 mg/dl) were
studied, Patients with a secondary form of the disease, Henoch-
Schönlein purpura or cirrhosis of the liver were excluded.
Patients were selected from the outpatient clinics of the Depart-
ments of Nephrology of the G. Bosco Hospital in Turin (25
cases) and of the S. Maria delle Croci Hospital in Ravenna (24
cases), Italy. Thirty-six normal subjects (21 males, 15 females),
coming from both cities, were also evaluated. Clinical data of
the study population are reported in Table 1. Arterial pressure
was measured by means of a standard sphygmomanometer after
five minutes of rest in the sitting position, before blood sampling
for erythrocyte Na,Li countertransport analysis. Values repre-
sent the mean of three consecutive readings. Patients were
considered hypertensive when diastolic pressure was 95 mm
Hg or when already treated by antihypertensive drugs, Eleven
patients were on antihypertensive therapy (angiotensin I con-
verting enzyme inhibitors in five cases, diuretics in six cases,
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Table 1. Clinical features of control subjects and patients with IgA
nephropathy
Patients with IgA nephropathy
Controls Normotensive Hypertensive
Number of cases 36 29 20
Males/females 21/15 18/11 14/6
Age years 36,8 1.6 34.3 2.6 43.3 2.5a
Body mass index kg/rn2 22.9 0.4 23.3 0.7 24.8 0.5
Time from clinical onset — 61 12 112 15b
months
beta-blockers in three cases and calcium antagonists in two
cases).
Weight and height were measured with a beam balance scale
with patients shoeless and wearing light clothing.
Since a reliable family history of hypertension was available
only in a minority of patients, this parameter was not taken into
account.
Erythrocyte Na,Li countertransport
All assays were performed in Turin. Heparinized blood
samples taken in Ravenna were shipped at 4°C to the laboratory
in Turin within six hours, and processed in the same day.
Na,Li countertransport was assayed, following Canessa et al
[1], measuring lithium effiux from lithium-loaded cells into
lithium-free media containing either sodium or magnesium. The
difference between lithium effiux into sodium-containing and
sodium-free media was taken as a measure of the maximum rate
of Na,Li countertransport. Red cells were loaded to contain at
least 5 mmol/liter lithium, sufficient to reach the Vmax of' Li
effiux stimulated by extracellular sodium. Packed red cells were
incubated for three hours at 37°C in a medium containing: (mM)
LiCl 150, glucose 10 and TRIS-Mops (pH of 7.4 at 37°C) 10.
Then, 0.5 ml of loaded red cells, suspended in a magnesium-
sucrose medium (75 mrt MgCI, 85 m sucrose) at a hematocrit
of 10 to 12% was added to tubes containing 1 ml of two different
efflux media. The sodium medium contained: (mM) 150 NaCI,
glucose 10 and TRIS-Mops (pH of 7.4 at 37°) 10, ouabain 0.1,
bumetanide 0.02. In the sodium-free medium NaCI was re-
placed by 75 mi MgCl and 85 m sucrose. For each effiux
medium, external Li concentrations were measured at time 0
and after one hour of incubation at 37°, by means of a Perkin
Elmer model 2380 atomic absorption spectrophotometer. It
should be noted that although the intracellular concentration of
lithium is sufficient to reach the Vmax of lithium efflux, the
external sodium concentration is not, since after mixing of the
suspending medium the final sodium concentration would be
about 100 mmollliter, which would give a Na,Li countertrans-
port value of about 75 to 80% of that at 140 mmol/liter of sodium
[20, 21]. However, we used this method since most previous
works have been carried out under similar experimental condi-
tions.
Other measurements
Serum concentration of creatinine was determined by Jeffe's
method (IL, Italy), total cholesterol and triglycerides were
Control subjects Patients with gA nephropathy
Normotensive Hypertensive
Fig. 1. Erythrocyte Na,Li countertransport in normal subjects and in
normotensive and hypertensive patients with IgA nephropathy. Bars
represent mean values.
measured by means of an ERIS Autoanalyzer 6170, and plasma
potassium by flame photometry; all measurements were carried
out in fasting samples. Urinary proteins were determined by the
Biuret-EDTA method (Sclavo, Italy).
Hyperlipidemia was defined as a plasma total cholesterol
concentration >200 mgldl and/or plasma triglycerides >172
mg/dl.
Statistical analysis
Data are presented as mean and SEM or as median and ranges
for not normally distributed variables. Results were analyzed
with two-tailed Student's t-test or Mann-Whitney U test when
appropriate. Two-way analysis of variance was also used.
Relationship between different variables was tested by univari-
ate linear regression analysis. Multivariate analysis was carried
out with stepwise logistic regression.
3.
Results
Main results are reported in Figure 1 and in Tables 1 through
Erythrocyte Na,Li countertransport was significantly higher
in the whole group of patients compared with normal subjects
(267 11 vs. 211 11 /Lmol/liter RBC/hr; P < 0.0001).
Twenty-nine patients with IgA nephropathy were classified
P < 0.0001
Values are means and SEM.
a p < 0.03 vs. controls and P = 0.02 vs. normotensive patients
b p = 0.01 vs. normotensive patients
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Table 2. Laboratory data of normotensive and hypertensive patients
with IgA nephropathy
Patients with IgA nephropathy
PNormotensive Hypertensive
Number of cases 29 20
Creatinine mg/dl 0.96 0.03 1.12 0.04 0.003
Potassium mmol/ 4.27 0.05 4.03 0.07 0.017
liter
Cholesterol mg/dl 193 8 223 II 0.029
Triglycerides mg/dl 121 12 187 32 0.037
Proteinuria glday 0.15 (0.04—1.5) 0.9 (0.1—6.5) 0.003
Values are median (ranges) for proteinuria and means (sEM) for other
variables.
as normotensive and 20 as hypertensive. The activity of Na,Li
countertransport was significantly higher in erythrocytes from
hypertensive than from normotensive patients (P =0.002) and
normal subjects (P 0.0001), (values respectively 309 17; 241
12 and 211 11 mol/liter RBC/hr). Conversely, normoten-
sive patients with IgA nephropathy did not differ from controls
regarding the Na,Li countertransport rate (Fig. 1).
Hypertensive patients were significantly older than nor-
motensive, had significantly higher values of plasma creatinine,
proteinuria, total serum cholesterol and serum triglycerides.
Plasma potassium concentration was slightly but significantly
lower in hypertensive than in normotensive patients. This was
due to the lower values recorded in the six patients treated with
diuretics, although this did not reach significance (Table 3).
However erythrocyte Na,Li countertransport activity was not
influenced by the antihypertensive treatment (Table 3).
Plasma lipids and potassium were not significantly different
between hypertensive patients treated with diuretics and those
taking other drugs or not treated.
The interval between the clinical onset of the nephropathy
and the time of the study was significantly higher for hyperten-
sive than for normotensive patients.
When blood pressure status was entered in a multiple step-
wise logistic regression analysis as the dependent variable with
Na,Li countertransport activity, age, serum creatinine, protein-
uria, cholesterol, triglycerides, plasma potassium and time from
onset as independent variables, an independent significant
association persisted for Na,Li countertransport (P = 0.002)
proteinuria (P = 0.006), plasma potassium (P = 0.006) and age(P = 0.029). Other tested variables were not independently
related to blood pressure status.
Hyperlipidemia was found in 29 patients (16 had high total
serum cholesterol levels, 5 hypertriglyceridemia and 8 both
abnormalities). Hyperlipidemic patients had an erythrocyte
Na,Li countertransport activity significantly higher than nor-
molipidemic (P = 0.005) and controls (P = 0.001) (values
respectively 295 14; 226 12 and 211 11 mol/liter
RBC/hr). A significant difference persisted also after having
excluded from the analysis the four patients with a nephrotic
range proteinuria and those assuming diuretics and/or beta-
blockers (data not shown). Accordingly, in the whole group of
patients erythrocyte Na,Li countertransport was significantly
directly correlated with total serum cholesterol (r = 0.45; P =
0.0012) and serum triglycerides (r = 0.44; P = 0.0017).
Analysis of variance showed that there was a significant
Table 3. Erythrocyte Na,Li countertransport activity and selected
biochemical parameters in hypertensive patients with IgA
nephropathy, grouped according to the antihypertensive therapy
Hypertensive patients with IgA nephropathy
Treated with
other anti-
Treated with hypertensive
Not treated diuretics drugs
Number of cases 9 6 5
Na,Li CNT 292 (180—482) 312 (216—407) 312 (241—331)
jtmol/liter/RBC/h
Plasma potassium 4.0 (3.8—4.5) 3.9 (3.3—4.1) 4.0 (3.8—4.7)
mmol/liter
Cholesterol mg/dI 260 (172—313) 203 (140—285) 220 (148—246)
Triglycerides mg/dl 148 (66—333) 137 (65—302) 130 (117—696)
Data are median and ranges.
effect on Na,Li countertransport of both hypertension (F =
7.12; P = 0.0106) nd hyperlipidemia (F = 13.5; P = 0.0006).
Discussion
Our results indicate that among patients with primary IgA
nephropathy those with arterial hypertension have a rate of
erythrocyte Na,Li countertransport significantly higher than
normotensive patients and normal subjects. Conversely, nor-
motensive patients did not differ from controls regarding the
Na,Li countertransport rate.
Eleven out of the twenty patients with high blood pressure
were taking antihypertensive drugs at the time of the study; this
is unlikely to have influenced Na,Li countertransport activity,
since the results were similar between treated and untreated
subjects. Moreover, other authors have reported that antihy-
pertensive drugs, including diuretics, beta-blockers and anglo-
tensin I converting enzyme inhibitors have no effect on red cell
Na,Li countertransport [22—231.
Our hypertensive patients differed significantly from nor-
motensive for many other parameters, including age, plasma
creatinine, urinary protein excretion, total serum cholesterol,
serum triglycerides, plasma potassium and the interval between
clinical onset of the nephropathy and the time of the study. The
difference of plasma potassium may be ascribed to the drug
treatment. In fact patients treated with diuretics had slightly
lower potassium levels.
Stepwise logistic regression analysis showed that an indepen-
dent significant association with blood pressure status persisted
for Na,Li countertransport, proteinuria, plasma potassium and
age.
Since elevated erythrocyte sodium-lithium countertransport
activity is considered to be a genetic marker of essential
hypertension [1, 21, these results suggest that arterial hyperten-
sion may be at least in part genetically determined in patients
with IgA nephropathy and without marked impairment of renal
function.
Accordingly, Carr, Thomas and Wilkinson [24] found that of
23 patients with renal disease and hypertension, 43% had Na,Li
countertransport greater than normal control range, and this
was related to a family history of both hypertension and
cardiovascular events.
Recently it has been reported that patients with IgA nephrop-
athy and a family history of hypertension have a significantly
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increased occurrence of arterial hypertension, chronic renal
failure and renal vascular lesions [251.
Our data also fit with the observation that the prevalence of
hypertension is significantly higher in parents of patients with
primary chronic glomerulonephritis, including IgA nephrop-
athy, than in parents of control subjects [19].
The mechanism by which raised Na,Li countertransport is
related to the pathophysiology of hypertension is unknown.
Possible links include increased proximal tubular sodium ab-
sorption [26, 271, altered adrenal and renal vascular response to
angiotensin II [281, reduced renin suppression by saline and
angiotensin II [28], and elevated plasma renin activity [29, 301.
Erythrocyte Na,Li countertransport was significantly ele-
vated in our hyperlipidemic patients, and was significantly
positively correlated with total serum cholesterol and triglycer-
ides, confirming previous observations in non-nephropathic
subjects [31—34] or insulin-dependent diabetic patients [111.
These correlations also persisted after having excluded patients
with nephrotic range proteinuria and those taking drugs which
could interfere with plasma lipids.
It is not clear whether hyperlipidemia influence erythrocyte
Na,Li countertransport activity or it simply reflects an associ-
ation.
However, Can et al [34], while studying patients with hyper-
tension and hyperlipidemia and their first degree relatives,
found that raised Na,Li countertransport was linked with both
hypertension and hyperlipidemia. They suggested that raised
plasma lipids and faster erythrocyte Na,Li countertransport
may both be the result of an abnormal cell lipid metabolism.
In our study, analysis of variance confirmed that in patients
with IgA nephropathy, both hypertension and hyperlipidemia
were independently associated with increased Na,Li counter-
transport activity.
Thus, although there is a great overlap between the hyper-
tensive and normotensive patients, high erythrocyte Na,Li
countertransport may identify a subset of patients with IgA
nephropathy with hypertension and a more atherogenic lipid
profile, which could play a role in the development of renal
vascular and glomerular lesions, favoring non-immunologic
progression of the disease [35].
A possible further speculation is that elevated cellular Na,Li
countertransport could induce, in the presence of immunologi-
cal abnormalities, the development of an active glomerular
disease through other mechanisms, besides higher arterial pres-
sure and plasma lipid abnormalities. In fact, Na,Li counter-
transport may be a mode of operation of the Na,H exchanger
system [261, which is involved in the control of cell growth and
protein synthesis [361. If present in mesangial cells, an overac-
tivity of this ion transport system could facilitate both hyper-
trophy and hyperplasia following an immunologic stimulus,
resulting in a more active disease.
A similar sequence of events has been hypothesized to occur
in the pathogenesis of nephropathy in type I diabetes, in
response to metabolic disregulation. In fact, an elevation of
erythrocyte Na,Li countertransport activity has been found in
type I diabetic patients with evidence of glomerular hyperfiltra-
tion [37], nephropathy and/or hypertension [9—13]. Recent
evidence has also been provided that essential hypertensive
patients with high erythrocyte Na,Li countertransport activity
have renal abnormalities, such as an increase of glomerular
filtration rate, kidney volume and urinary albumin excretion,
which could predispose to the late development of renal disease
[8].
Our study does not allow us to evaluate this hypothesis,
however, in nine patients with IgA nephropathy, excluded from
the present series because of renal insufficiency, median (rang-
es) red cell Na,Li countertransport activity was 301 (136 to 453)
jmol/liter RBC/hr, a value as high as that found in our hyper-
tensive patients without significant impairment of renal func-
tion.
In conclusion, the results of this study suggest the hypothesis
that a high erythrocyte Na,Li countertransport rate may be a
marker of an increased risk of developing arterial hypertension,
lipid abnormalities, and perhaps a more severe renal disease in
patients with IgA nephropathy. However, to confirm these
findings, further studies comparing patients matched for age
and duration of disease will be necessary.
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